<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156442">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01962792</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1119-CA</org_study_id>
    <secondary_id>PCI-32765 [Sponsor]</secondary_id>
    <nct_id>NCT01962792</nct_id>
  </id_info>
  <brief_title>Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onyx Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacyclics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 is a dose escalation study to evaluate the safety and recommended Phase 2b dose of
      ibrutinib in combination with carfilzomib with and without dexamethasone.

      Phase 2b will be a randomized, double-blind, placebo controlled study to evaluate the
      efficacy of ibrutinib and carfilzomib with or without dexamethasone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other
      than T cells and is necessary for downstream signal transduction from various hematopoietic
      receptors including the B cell receptor as well as some Fc, chemokine, and adhesion
      receptors, and is crucial for both B cell development and osteoclastogenesis. Although
      down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from
      many myeloma patients and some cell lines. PCI-32765 is a potent and specific inhibitor of
      Btk currently in Phase 2 and 3 clinical trials. The current study is designed and intended
      to determine the safety and efficacy of PCI-32765 in combination with carfilzomib
      (Kyprolis™) with and without dexamethasone in subjects with MM.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase 1: Determine the safe and recommended dose of ibrutinib when combined with carfilzomib</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Maximum tolerated doses (MTD) and recommended Phase 2 dose (RP2D) of ibrutinib in combination with carfilzomib with and without dexamethasone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: To evaluate the safety of ibrutinib in combination of carfilzomib</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicities associated with the combination of ibrutinib and carfilzomib with and without dexamethasone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2b:  To evaluate efficacy using progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy of ibrutinib and carfilzomib with and without dexamethasone compared to placebo and carfilzomib with or without dexamethasone on the duration of progression-free survival (PFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: To evaluate efficacy using Overall Response Rate (ORR) and Duration of Response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Response Rate (ORR) (≥ partial response (PR); according to the International Working Group (IMWG) criteria
Duration of Response (DOR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: To evaluate efficacy of ibrutinib in combination with carfilzomib using Overall Response Rate (ORR) and Duration of Response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the treatment groups in terms of the following:
Overall response rate (ORR)
Duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: To evaluate the safety and tolerability of ibrutinib in combination with carfilzomib with or without dexamethasone</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: To evaluate the efficacy of ibrutinib in combination with carfilzomib using Overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the treatment groups in terms of Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b: To evaluate the efficacy of ibrutinib in combination with carfilzomib using Time to Progression (TTP)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the treatment groups in terms of Time to Progression (TTP)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">223</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Phase 1 - Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibrutinib PO + carfilzomib IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 - Dose Level 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibrutinib PO + carfilzomib IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 - Dose Level 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibrutinib PO + carfilzomib IV + dexamethasone PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Dose Level 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibrutinib PO + carfilzomib IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Dose Level 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibrutinib PO + carfilzomib IV + dexamethasone PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibrutinib PO + carfilzomib IV (with or without dexamethasone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo + carfilzomib IV (with or without dexamethasone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <arm_group_label>Phase 1 - Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1 - Dose Level 2a</arm_group_label>
    <arm_group_label>Phase 1 - Dose Level 2b</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 3a</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 3b</arm_group_label>
    <arm_group_label>Phase 2: Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <arm_group_label>Phase 1 - Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1 - Dose Level 2a</arm_group_label>
    <arm_group_label>Phase 1 - Dose Level 2b</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 3a</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 3b</arm_group_label>
    <arm_group_label>Phase 2: Arm A</arm_group_label>
    <arm_group_label>Phase 2: Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Phase 2: Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Phase 1 - Dose Level 2b</arm_group_label>
    <arm_group_label>Phase 1: Dose Level 3b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Measurable disease of MM as defined by at least ONE of the following:

               1. Serum monoclonal protein (SPEP) ≥1 g/dL

               2. Urine M-protein &gt;200 mg/24 hrs

               3. Serum free light chain (SFLC): involved FLC ≥10 mg/dL (≥100 mg/L) AND abnormal
                  kappa to lambda serum free light chain ratio

          -  Relapsed or relapsed and refractory MM after receiving at least 2 previous therapies,
             including an immunomodulator and bortezomib and had either no response or documented
             disease progression (according to IMWG criteria) to the most recent treatment regimen

          -  Adequate hematologic and renal function

          -  ECOG performance status of ≤ 2

        Exclusion Criteria:

          -  Subject must not have primary refractory disease

          -  Plasma cell leukemia, primary amyloidosis or POEMS syndrome

          -  Unable to swallow capsules or disease significantly affecting gastrointestinal
             function

          -  Requires anti-coagulation with warfarin or a vitamin K antagonist

          -  Requires treatment with strong CYP3A inhibitors
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lipo Chang</last_name>
    <phone>855-427-8846</phone>
    <email>medinfo@pcyc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCI-32765</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed Refractory Multiple Myeloma</keyword>
  <keyword>Bruton's Tyrosine Kinase</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Dexamethasone</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
